

1 **Protein-truncating variants in *BSN* are associated with severe adult-onset obesity,**
2 **type 2 diabetes and fatty liver disease**

3 Yajie Zhao*¹, Maria Chukanova*², Katherine A Kentistou*¹, Zammy Fairhurst-Hunter³, Anna
4 Maria Siegert², Raina Jia¹, Georgina Dowsett², Eugene J Gardner¹, Felix R Day¹, Lena R
5 Kaisinger¹, Yi-Chun Loraine Tung², Brian Yee Hong Lam², Hsiao-Jou Cortina Chen², Quanli
6 Wang³, Jaime Berumen-Campos⁴, Pablo Kuri-Morales^{4,5}, Roberto Tapia-Conyer⁴, Jesus
7 Alegre-Diaz⁴, Jonathan Emberson⁶, Jason M Torres⁶, Rory Collins⁶, Danish Saleheen^{7,8},
8 Katherine R Smith³, Dirk S Paul³, Florian Merkle², Nick J Wareham¹, Slavé Petrovski³, Steve
9 O'Rahilly², Ken K Ong*¹, Giles S H Yeo*² and John R B Perry*^{2,1}

10

11 **Affiliations**

12 ¹MRC Epidemiology Unit, Wellcome-MRC Institute of Metabolic Science, University of
13 Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK,

14 ²Metabolic Research Laboratory, Wellcome-MRC Institute of Metabolic Science, University
15 of Cambridge School of Clinical Medicine, Cambridge CB2 0QQ, UK,

16 ³Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D,
17 AstraZeneca, Cambridge, UK,

18 ⁴Experimental Medicine Research Unit, Faculty of Medicine, National Autonomous
19 University of Mexico, Copilco Universidad, Coyoacán, 4360 Ciudad de México, Mexico,

20 ⁵Instituto Tecnológico de Estudios Superiores de Monterrey, Av. Eugenio Garza Sada 2501
21 Sur, Tecnológico, 64849 Monterrey, N.L., Mexico,

22 ⁶Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, England,
23 UK,

24 ⁷Center for Non-Communicable Diseases, Karachi, Sindh, Pakistan,

25 ⁸Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA

26

27 * denotes equal contribution

28 Correspondence to John R B Perry (John.Perry@mrc-epid.cam.ac.uk)

29

30 **Abstract**

31 Obesity is a major risk factor for many common diseases and has a significant heritable
32 component. While clinical and large-scale population studies have identified several genes
33 harbouring rare alleles with large effects on obesity risk, there are likely many unknown
34 genes with highly penetrant effects remaining. To this end, we performed whole exome-
35 sequence analyses for adult body mass index (BMI) in up to 587,027 individuals. We
36 identified rare, loss of function variants in two genes – *BSN* and *APBA1* – with effects on
37 BMI substantially larger than well-established obesity genes such as *MC4R*. One in ~6500
38 individuals carry a heterozygous protein truncating variant (PTV) in *BSN*, which confers a
39 6.6, 3.7 and 3-fold higher risk of severe obesity (BMI >40kg/m²), non-alcoholic fatty liver
40 disease and type 2 diabetes, respectively. In contrast to most other obesity-related genes,
41 rare variants in *BSN* and *APBA1* had no apparent effect on childhood adiposity.
42 Furthermore, *BSN* PTVs magnified the influence of common genetic variants associated with
43 BMI, with a common polygenic score exhibiting an effect on BMI twice as large in *BSN* PTV
44 carriers than non-carriers. Finally, we explored the plasma proteomic signatures of *BSN* PTV
45 carriers as well as the functional consequences of *BSN* deletion in human iPSC-derived
46 hypothalamic neurons. These approaches highlighted a network of differentially expressed
47 genes that were collectively enriched for genomic regions associated with BMI, and suggest
48 a role for degenerative neuronal synaptic function and neurotransmitter release in the
49 etiology of obesity.

50

51 Introduction

52 Over one billion people worldwide live with obesity, a global health challenge that is rapidly
53 increasing in scale^{1,2}. Obesity is the second leading cause of preventable death, increasing
54 the risks of diseases such as type 2 diabetes, cardiovascular disease and cancer^{1,3}.

55 Understanding the full range of social, psychological, and biological determinants of energy
56 intake and expenditure will be key to tackling this epidemic.

57 Early studies in mice highlighted the role of the leptin-melanocortin pathway in appetite and
58 body weight regulation⁴, which led to candidate gene sequencing studies of rare individuals
59 with severe early-onset obesity. Those studies identified rare loss of function mutations in
60 key components of this pathway as causes of severe, early-onset obesity⁵, the most
61 common of which impact the melanocortin 4 receptor (*MC4R*)^{6,7}. In parallel, using a
62 ‘hypothesis-free’ approach, large-scale population-based genome-wide association studies
63 (GWAS) have identified hundreds of common genetic variants associated with body mass
64 index (BMI) in adults⁸. Those variants are mostly non-coding and are enriched near genes
65 expressed in the brain⁹. Individually, the effect of each variant is small, and cumulatively the
66 ~1000 common variants identified to date explain only ~6% of the population variance in
67 BMI⁸. The recent emergence of whole exome sequence (WES) data at the population scale
68 has enabled exome-wide association studies (ExWAS), leading to a convergence of
69 common and rare variant discoveries. In a landmark study, Akbari *et al* used WES data in
70 ~640,000 individuals to identify rare protein-coding variants in 16 genes associated with
71 BMI¹⁰. These included genes with established roles in weight regulation (*MC4R*, *GIPR* and
72 *PCSK1*) in addition to novel targets, such as *GPR75*, in which loss-of-function mutations are
73 protective against obesity in humans and mice¹⁰.

74 The current study is an ExWAS for BMI using WES data of 419,668 UK Biobank
75 participants. Although this represents a subset of the exomes previously reported by Akbari
76 *et al*¹⁰, we were motivated by recent work demonstrating that in the context of gene-burden
77 analysis¹¹, the various choices around how one could define a qualifying rare variant can
78 highlight biologically relevant genes at exome-wide significance missed using alternative
79 definitions¹². Consistent with this, our approach identified novel rare variant associations with
80 *BSN* and *APBA1*, which we replicated in independent WES data from 167,359 individuals of
81 non-European genetic ancestries. The detected rare protein truncating variants in *BSN* and
82 *APBA1* have larger effects than other previously reported ExWAS genes¹⁰, and our findings
83 collectively suggest an emerging role for degenerative neuronal synaptic function and
84 neurotransmitter release in the etiology of obesity.

85

86

87 Results

88 To identify rare variants associated with adult BMI, we performed an ExWAS using genotype
89 and phenotype data from 419,668 individuals of European ancestry from the UK Biobank
90 study¹³. Individual gene-burden tests were performed by collapsing rare (MAF<0.1%)
91 genetic variants across 18,658 protein-coding genes. We tested three categories of variants
92 based on their predicted functional impact: high-confidence Protein Truncating Variants
93 (PTVs), and two overlapping missense masks that used a REVEL¹⁴ score threshold of 0.5 or
94 0.7. This yielded a total of 37,691 gene tests with at least 30 informative rare allele carriers,
95 corresponding to a multiple-test corrected statistical significance threshold of $P < 1.33 \times 10^{-6}$
96 (0.05/37,691).

97 Genetic association testing was performed using BOLT-LMM¹⁵, which identified a total of
98 nine genes meeting this threshold for significant association with adult BMI (**Table S1**). Our
99 gene-burden ExWAS appeared statistically well-calibrated, as indicated by low exome-wide
100 test statistic inflation [$\lambda_{GC} = 1.05 - 1.15$] and by the absence of significant associations with any
101 synonymous variant masks (**Figure S1-2**). Five of our identified associations were previously
102 reported – PTVs in *MC4R*, *UBR2*, *KIAA1109*, *SLTM* and *PCSK1*¹⁰. At the other four genes,
103 heterozygous PTVs conferred higher risk for adult BMI: *BSN* (effect=3.05 kg/m², se=0.54,
104 $P = 2 \times 10^{-8}$, carrier N=65), *TOX4* (3.61, se=0.71, $P = 3.1 \times 10^{-7}$, carrier N=39), *APBA1* (2.08,
105 se=0.42, $P = 6.1 \times 10^{-7}$, carrier N=111) and *ATP13A1* (1.82, se=0.37, $P = 1.1 \times 10^{-6}$, carrier
106 N=139). For two of these genes, *BSN* and *ATP13A1*, we also found supporting evidence
107 from common genetic variants at the same locus associated with BMI (**Figure S3**) – non-
108 coding alleles ~200kb upstream of *BSN* (rs9843653, MAF=0.49, beta=-0.13 kg/m²,
109 $P = 9.5 \times 10^{-46}$) and 400kb upstream of *ATP13A1* (rs72999063, MAF=0.16, beta=0.09 kg/m²,
110 $P = 3.2 \times 10^{-13}$, **Table S2**). Both of these GWAS signals were also associated with blood
111 expression levels of *BSN* and *ATP13A1*, respectively¹⁶ (**Table S2**), and the BMI associations
112 were replicated in independent GWAS data from the GIANT consortium⁹ (**Figure S4, Table**
113 **S2**). We found no evidence of rare variant associations with BMI for any other genes at
114 these GWAS loci (**Table S3**).

115 We aimed to replicate our novel gene-burden rare variant associations in independent WES
116 data from 167,359 individuals of non-European ancestry from the Mexico City Prospective
117 Study (MCPS)^{17,18} and the Pakistan Genomic Resource (PGR) study (**Table S4, Figure 1**).
118 We observed supportive evidence for two of the four novel genes identified above – 32 *BSN*
119 PTV carriers had a mean 2.8 kg/m² (se=0.84, $P = 9.4 \times 10^{-4}$) higher BMI than non-carriers, and
120 20 *APBA1* PTV carriers had a mean 2.33 kg/m² (se=1.05, $P = 0.03$) higher BMI. These effect
121 sizes were remarkably similar to those observed in UK Biobank (3.05 kg/m² and 2.08 kg/m²
122 for *BSN* and *APBA1*, respectively).

123 The effect of *BSN* is larger than any previously reported ExWAS gene on BMI (**Figure 2**),
124 and substantially increased the risks of obesity in UK Biobank; (*BSN* OR=3.04 [95%
125 confidence interval 1.87-4.94], $P=7.7 \times 10^{-6}$, 49% case prevalence; *APBA1* OR=2.14 [1.46-
126 3.13], $P=8.5 \times 10^{-5}$, 41% case prevalence) and for *BSN* also increased the risk of severe
127 obesity (OR=6.61 [3.01-14.55], $P=2.6 \times 10^{-6}$, 11% case prevalence) but not for *APBA1*
128 (OR=1.91 [0.70-5.19], $P=0.20$, 4% case prevalence, **Figure 3**). Association statistics for
129 individual variants in *BSN* and *APBA1* in UK Biobank are shown in **Figure 1B** and **Table S5**.
130 The gene-level associations between *BSN* and *APBA1* and BMI were not driven by single
131 high-confidence (HC) PTVs (**Table S6**), and carriers appeared to be geographically
132 dispersed across the UK (**Figure S5**).

133 We next sought to understand the broader phenotypic profile of carriers of PTVs in *BSN* and
134 *APBA1*. Both genes showed diverse associations with body composition, with higher fat and
135 lean mass across body compartments (**Table S7**), but no association with adult height
136 ($P>0.05$) or waist-to-hip ratio adjusted for BMI ($P>0.05$). In contrast to almost all previously
137 reported obesity-associated genes, neither *BSN* or *APBA1* exhibited any association with
138 childhood body size or puberty timing ($P>0.05$), suggesting adult-onset effects on body
139 weight based on the phenotypes available in UK Biobank. In UK Biobank, carriers of PTVs in
140 *BSN* also had higher risk of type 2 diabetes (T2D) – *BSN* OR=3.03 (95% CI [1.60-5.76], $P=$
141 7.1×10^{-4} , 18% case prevalence) – an effect size comparable to previously reported genes for
142 T2D^{19,20}. A broader phenome-wide analysis across 11,693 traits revealed a number of other
143 associations (**Table S8**); notably *BSN* PTV carriers had a substantially higher risk of non-
144 alcoholic fatty liver disease (NAFLD) - as defined by a Fatty Liver Index (FLI) ≥ 60 ²¹ or
145 Hepatic Steatosis Index (HSI) > 36 ²² – compared to non-carriers (OR=3.73 (95% CI [2.26-
146 6.16], $P=8.4 \times 10^{-7}$, 45% case prevalence).

147 Previous studies reported that common BMI-associated alleles did not modify the
148 penetrance of rare variants on BMI or obesity¹⁰. To evaluate whether this was true also for
149 *BSN* and *APBA1*, we created a common variant polygenic score (PGS) in UK Biobank, using
150 individual variant effect estimates obtained from independent GIANT consortium GWAS
151 data⁹. By testing the interaction between the PGS and rare variant carrier status in a linear
152 regression model, we observed significant effect modification by *BSN* PTVs ($P=0.01$,
153 **Figure S6**), but not *APBA1* ($P=0.22$). Carriers of *BSN* PTVs showed double the effect size of
154 the PGS on BMI (0.6 BMI standard deviations per unit increase in PGS, equivalent to 2.9
155 kg/m²) than non-carriers (0.3 standard deviations, equivalent to 1.4 kg/m²).

156 To explore the putative biological mechanisms through which *BSN* and *APBA1* might exert
157 their effects, we first characterized the plasma proteomic signature of PTV carriers using

158 Olink data on 1,463 circulating proteins available in ~50,000 UK Biobank participants^{23,24}.
159 We identified 6 and 17 PTV carriers with available proteomics data for *BSN* and *APBA1*,
160 respectively. No plasma proteins were associated with *APBA1* carrier status after multiple-
161 test correction ($P < 3.42 \times 10^{-5}$ (0.05/1,463)), however *BSN* PTV carriers had higher levels of
162 lymphotoxin alpha (LT- α , previously known as TNF- β) than non-carriers (effect=1.07,
163 se=0.183, $P=5.3 \times 10^{-9}$) (**Table S9**). Furthermore, circulating LT- α levels were positively
164 associated with BMI (1.18 kg/m² per 1 SD higher LT- α , $P=7.6 \times 10^{-122}$) and common genetic
165 variants at the *LTA* locus were associated with BMI (rs3130048, MAF=0.72, beta=-0.10
166 kg/m²/allele, $P=1.10 \times 10^{-23}$). We repeated these analyses using the common BMI-associated
167 variant (rs9843653) at *BSN* and identified 23 associated proteins, the most significant of
168 which was Semaphorin-3F (-0.03 SD per BMI-increasing allele, $P=6.7 \times 10^{-45}$), a member of
169 the semaphorin family which has been previously implicated in obesity etiology²⁵. In total, 10
170 of these 24 protein-encoded genes (including *SEMA3F* and *LTA*) were also implicated by
171 common variant signals for BMI (**Table S10**).

172 Finally, we explored the functional consequences of *BSN* deletion, which is highly expressed
173 in the brain, by generating CRISPR-Cas9 edited human iPSC hypothalamic neurons that
174 were heterozygous for *BSN* loss of function (**Methods**). Numbers of differentiated *BSN*^{+/-}
175 cells were lower than WT cells (2,924 *BSN*^{+/-} and 18,010 WT); however, on visual inspection
176 there was no apparent morphological effect on neuronal differentiation (**Figure S7**). To
177 assess transcriptional differences between these cell populations, we performed single
178 nucleus RNAseq across all 20,934 hypothalamic cells differentiated from human iPSCs. A
179 UMAP plot of the cells identified eight distinct clusters (**Figure S8**), of which two clusters
180 (clusters 1 and 5, encompassing 4,991 cells) were enriched for *RBFOX3* (*NeuN*) expression,
181 a marker for mature neurons. These two clusters were also enriched for expression of *BSN*
182 and its binding partner *Piccolo* (*PCLO*), and were therefore separated and re-clustered for
183 further analysis (**Figure S8**). This produced a further five clusters, including 2,712 WT and
184 343 *BSN*^{+/-} cells, which we selected for analysis of differential gene expression (defined by
185 corrected $P < 0.05$ and $\text{Log}_2\text{FC} > 1$ or < -1). These analyses highlighted 251 differentially-
186 expressed genes across one or more of the five clusters (**Table S11**), including genes with
187 established roles in obesity regulation, such as members of the semaphorin gene family²⁵
188 and *ALK*²⁶. Pathway enrichment analyses across differentially-expressed genes highlighted
189 a number of biological processes (**Table S12**), with 'synapse organization' and 'negative
190 regulation of neuron projection development' the most significantly enriched pathways in
191 clusters 1 and 2, respectively. Collectively, differentially-expressed genes within these two
192 clusters (1 & 2) were also enriched for common variant associations with BMI (**Table S13-**
193 **14**).

194 **Discussion**

195 We identified that rare PTVs in *APBA1* and *BSN* are associated with a substantial increase
196 in adult BMI and higher risk of obesity in adults, but not in childhood. Rare PTVs in *BSN*
197 were also found to be associated with higher risks for T2D and NAFLD. The associations
198 with adult BMI were confirmed in independent cohorts and also supported by mapping of
199 common variant signal to whole-blood eQTLs for *APBA1* and *BSN*.

200 *APBA1* and *BSN* are among the few genetic determinants of adult-onset obesity. Although
201 childhood adiposity was assessed here by subjective recall, this trait is reported to show high
202 genetic correlation with measured childhood BMI and hence is a valid indicator for genetic
203 analyses²⁷. *APBA1* encodes a neuronal adapter protein that interacts with the Alzheimer's
204 disease-associated gene amyloid precursor protein (*APP*). It has a putative role in signal
205 transduction as a vesicular trafficking protein with the potential to couple synaptic vesicle
206 exocytosis to neuronal cell adhesion²⁸. *BSN* encodes Bassoon, a scaffolding protein
207 essential for the organization of the presynaptic cytoskeleton and for exocytosis-mediated
208 neurotransmitter release²⁹. *Bsn* knockout in mice reduces excitatory synaptic transmission
209 because vesicles are unable to efficiently fuse with the synaptic membrane³⁰. *BSN* is
210 expressed primarily in the brain and is reportedly upregulated in frontal lobes of patients with
211 multiple system atrophy, a progressive neurodegenerative disease³¹. Furthermore, rare
212 predicted-damaging missense mutations in *BSN* were reported in four patients with
213 progressive supranuclear palsy-like syndrome with features of multiple system atrophy and
214 Alzheimer's disease³². Hence, the links we identify here with adult-onset (rather than
215 childhood-onset) obesity may be consistent with the putative roles of *APBA1* and *BSN* in
216 ageing-related neurosecretory vesicle dysfunction and neurodegenerative disorders.

217 Previous studies reported additive effects of common and rare susceptibility alleles on BMI¹⁰,
218 but no evidence for epistatic interactions that are indicative of biological interaction. Notably,
219 we found that carriers of rare PTVs in *BSN* showed enhanced susceptibility to the influence
220 of a common genetic polygenic risk score for adult BMI. The mechanistic basis for this
221 statistical interaction is unclear. However, as the common genetic susceptibility to obesity is
222 thought to act predominantly via the central regulation of food intake^{9,33}, we hypothesize that
223 *BSN* might have widespread involvement in the synaptic secretion of neurotransmitters that
224 suppress appetite and increase satiety.


225 In conclusion, rare genetic disruption of *APBA1* and *BSN* have larger impacts on adult BMI
226 and obesity risk than heterozygous disruption of any other described obesity risk gene. Rare
227 PTVs in *APBA1* and *BSN* appear to preferentially confer risk to adult-onset obesity, which

228 we propose might be due to widespread vesicular dysfunction leading to reduced synaptic
229 secretion of neurotransmitters that suppress food intake.

230

231 **Figures**

232



233

234

235 **Figure 1 | Discovery and replication of novel rare variant associations with BMI in UK**


236 **Biobank.** (a) Effect size estimates have been converted to kg/m². Extended data can be

237 found in Table S1 and S4. (b) Variant-level associations between HC PTVs in *BSN* and

238 *APBA1* and BMI. The Y-axis shows trait increasing effects with a $-1 \cdot \log(10)$ p-value and trait

239 decreasing effects with a $\log(10)$ p-value. Dashed line denotes variants reaching a nominal

240 significance threshold $P < 0.05$.



241


242

243 **Figure 2 | Comparison of effect between replicated associations and previously**

244 **reported associations**¹⁰. The BMI effect size estimates are based on UK Biobank

245 participants only.

246



247

248 **Figure 3 | Distribution in BMI categories for the carriers and non-carriers of *BSN*,**
249 ***APBA1* or *MC4R* HC PTV carriers.** The BMI categories are classified according to the
250 WHO's guidance.

251

252 **Acknowledgements**

253

254 **Competing interests:** Z. F.-H., Q.W., K.R.S, D.S.P., and S.P. are current employees and/or
255 stockholders of AstraZeneca. J.R.B.P and E.G are employees and shareholders of Adrestia
256 Therapeutics.

257

258 **Funding:** The MCPS has received funding from the Mexican Health Ministry, the National
259 Council of Science and Technology for Mexico, the Wellcome Trust (058299/Z/99), Cancer
260 Research UK, British Heart Foundation, and the UK Medical Research Council
261 (MC_UU_00017/2). These funding sources had no role in the design, conduct, or analysis of
262 the study or the decision to submit the manuscript for publication.

263

264 We thank the participants and investigators in the UKB study who made this work possible
265 (Resource Application Number 26041; 9905) the UKB Exome Sequencing Consortium
266 (UKB-ESC) members AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, Bristol-
267 Myers Squibb, Pfizer, Regeneron and Takeda for funding the generation of the data; the
268 Regeneron Genetics Center for completing the sequencing and initial quality control of the
269 exome sequencing data; and the AstraZeneca Centre for Genomics Research Analytics and
270 Informatics team for processing and analysis of sequencing and phenotype data.

271

272 **Data Accessibility**

273

274 The UK Biobank phenotype and whole-exome sequencing data described here are publicly
275 available to registered researchers through the UKB data access protocol. Information about
276 registration for access to the data is available at: <https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access>. Data for this study were obtained under Resource Application
277 Numbers 26041 and 9905.

279

280 The Mexico City Prospective Study welcomes open access and collaboration data requests
281 from bona fide researchers. For more details on accessibility, the study's Data and Sample
282 Sharing policy may be downloaded (in English or Spanish) from
283 <https://www.ctsu.ox.ac.uk/research/mcps>. Available study data can be examined in detail
284 through the study's Data Showcase, available at <https://datashare.ndph.ox.ac.uk/mexico/>.

285

286 **Methods**

287 **UK biobank data processing and quality control**

288 We employed the same processing strategies as outlined in our previous paper to analyse
289 the whole-exome sequencing data and perform quality control steps¹⁹. We queried whole-
290 exome sequencing data from 454,787 individuals in the UK Biobank³⁴, excluding those with
291 excess heterozygosity, autosomal variant missingness on genotyping arrays $\geq 5\%$, or those
292 not included in the subset of phased samples as defined by Bycroft et al¹³.

293 The whole-exome sequencing data was stored as population-level VCF files, aligned to
294 GRCh38, and accessed through the UKBB RAP. In addition to the quality control measures
295 already applied to the released data, which were described by Backman et al.³⁴, we
296 conducted several extra QC procedures. Firstly, we used 'bcftools norm'³⁵ to split the
297 multiallelic sites and left-correct and normalise InDels. Next, we filtered out variants that
298 failed our QC criteria, including: 1) read depth < 7 , 2) genotype quality < 20 , and 3) binomial
299 test p-value for alternate allele reads versus reference allele reads ≤ 0.001 for
300 heterozygous genotypes. For InDel genotypes, we only kept variants with read depth ≥ 10
301 and genotype quality ≥ 20 . Variants that failed QC criteria were marked as missing (i.e., ./.).
302 After filtering, variants where more than 50% of genotypes were missing were excluded from
303 downstream analyses¹⁹.

304 The remaining variants underwent annotation using ENSEMBL Variant Effect Predictor
305 (VEP) v104³⁶ with the '-everything' flag, and additional plugins for REVEL¹⁴, CADD³⁷, and
306 LOFTEE³⁸. For each variant, a single ENSEMBL transcript was prioritised based on whether
307 the annotated transcript was protein-coding, MANE select v0.97³⁹, or the VEP Canonical
308 transcript. The individual consequence for each variant was then prioritised based on
309 severity as defined by VEP. Stop-gained, splice acceptor, and splice donor variants were
310 merged into a combined Protein Truncating Variant category, while annotations for missense
311 and synonymous variants were adopted directly from VEP. We only included variants on
312 autosomes and the X chromosome that were within ENSEMBL protein-coding transcripts
313 and within transcripts included on the UKBB WES assay in our downstream analysis.

314 Our analyses focused primarily on individuals of European genetic ancestry, and we
315 excluded those who withdrew consent from the study, resulting in a final cohort of 419,668
316 individuals.

317 **Exome-wide gene burden testing in the UK Biobank**

318 We used BOLT-LMM v2.3.6¹⁵ as our primary analytical tool to conduct the gene burden test.
319 To run BOLT-LMM, we first queried a set of genotypes with MAC > 100 which derived from
320 the genotyping arrays for the individuals with the WES data to build the null model. To
321 accommodate BOLT-LMM's requirement for imputed genotyping data rather than per-gene
322 carrier status, we developed dummy genotype files where each gene was represented by a
323 single variant. We then coded individuals with a qualifying variant within a gene as
324 heterozygous, regardless of the total number of variants they carried in that gene. We then
325 created the dummy genotypes for the MAF < 0.1% high confidence PTVs as defined by
326 LOFTEE, missense variants with REVEL > 0.5 and missense variants with REVEL > 0.7. We
327 then used BOLT-LMM to analyse phenotypes, using default parameters except for the
328 inclusion of the 'ImmInfOnly' flag. In addition to the dummy genotypes, we also included all
329 individual markers contained in WES data to generate the association test statistics for
330 individual variants. We used age, age², sex, the first 10 principal components as calculated
331 by Bycroft et al.¹³, and the WES released batch (50k, 200k, 450k) as covariates.

332 To check whether there is a single variant driving the association, we performed a leave-
333 one-out analysis for *BSN* and *APBA1* using linear regression in R v3.6.3 by dropping the HC
334 PTV variants contained in our analysis one by one. In addition, we also checked the
335 geographic distribution of *APBA1* and *BSN* HC PTV carriers.

336 **Replication of the findings in two independent non-European cohorts**

337 We tried to replicate our findings for the four novel genes in two independent non-European
338 exome-sequenced cohorts: Mexico City Prospective Study (MCPS) and The Pakistan
339 Genomic Resource (PGR) study.

340 Mexico City Prospective Study is a cohort study of 159,755 adults of predominantly Admixed
341 American ancestry. Participants were recruited between 1998 and 2004 aged 35 years or
342 older from two adjacent urban districts of Mexico City. Phenotypic data were recorded during
343 household visits, including height, weight, and waist and hip circumferences. Disease history
344 was self-reported at baseline, and participants are linked to Mexican national mortality
345 records. The cohort has been described in detail elsewhere^{17,18}. The MCPS study was
346 approved by the Mexican Ministry of Health, the Mexican National Council for Science and
347 Technology, and the University of Oxford.

348 The Pakistan Genomic Resource study has been recruiting participants aged 15-100 years
349 as cases or controls via clinical audits for specific conditions since 2005 from over 40
350 centres around Pakistan. Participants were recruited from clinics treating patients with
351 cardiometabolic, inflammatory, respiratory, or ophthalmological conditions. Information on

352 lifestyle habits, medical and medication history, family history of diseases, exposure to
353 smoking and tobacco consumption, physical activity, dietary habits, anthropometry, basic
354 blood biochemistry and ECG traits were recorded during clinic visits. DNA, serum, plasma,
355 and whole-blood samples were also collected from all study participants. The institutional
356 review board at the Center for Non-Communicable Diseases (IRB: 00007048,
357 IORG0005843, FWAS00014490) approved the study and all participants gave informed
358 consent.

359 Exome sequencing data for 141,046 MCPS and 37,800 PGR participants were generated at
360 the Regeneron Genetics Center and passed Regeneron's initial quality control (QC) that
361 included identifying sex discordance, contamination, unresolved duplicate sequences, and,
362 for MCPS, discordance with microarray genotype data. Genomic DNA underwent paired-end
363 75–base pair whole-exome sequencing at Regeneron Pharmaceuticals using the IDT xGen
364 v1 capture kit on the NovaSeq6000 platform. Conversion of sequencing data in BCL format
365 to FASTQ format and the assignments of paired-end sequence reads to samples were
366 based on 10-base barcodes, using bcl2fastq v2.19.0.

367 These exome sequences were processed at AstraZeneca from their unaligned FASTQ state.
368 A custom-built Amazon Web Services cloud computing platform running Illumina DRAGEN
369 Bio-IT Platform Germline Pipeline v3.0.7 was used to align the reads to the GRCh38
370 genome reference and perform single-nucleotide variant (SNV) and insertion and deletion
371 (indel) calling. SNVs and indels were annotated using SnpEff v4.3⁴⁰ against Ensembl Build
372 38.92. All variants were additionally annotated with their gnomAD MAFs (gnomAD v2.1.1
373 mapped to GRCh38)³⁸.

374

375 To further QC the sequence data, all MCPS and PGR exomes underwent a second screen
376 using AstraZeneca's bioinformatics pipeline which has been described in detail previously⁴¹.
377 Briefly, we excluded from analysis sequences that achieved a VerifyBamID freemix
378 (contamination) level of more than 4%, where inferred karyotypic sex did not match self-
379 reported gender, or where less than 94.5% of the consensus coding sequence (CCDS
380 release 22) achieved a minimum tenfold read depth. We further removed one individual from
381 every pair of genetic duplicates or monozygotic twins with a kinship coefficient > 0.45.
382 Kinship coefficients were estimated from exome genotypes using the --kinship function from
383 KING v2.2.3⁴². For MCPS we additionally excluded sequences with an average CCDS read
384 depth at least two standard deviations (SD) below the mean. After the above quality control
385 steps, there remained 139,603 (99.0%) MCPS and 37,727 (99.3%) PGR exomes.

386 In MCPS, we predicted the genetic ancestry of participants using PEDDY v0.4.2⁴³, with 1000
387 Genomes Project sequences as population references⁴⁴ and retain individuals with a
388 predicted probability of Admixed American ancestry ≥ 0.95 who were within 4 SD of the
389 means for the top four principal components (PCs). In PGR we retained individuals with a
390 predicted probability of South Asian ancestry ≥ 0.95 who were within 4 SD of the means for
391 the top four PCs. Following ancestry filtering, 137,059 (97.2%) MCPS and 36,280 (95.5%)
392 PGR exomes remained.

393 We assessed the association between BMI and weight quantitative traits with genotypes at
394 the four proposed novel genes of interest using a previously described gene-level collapsing
395 analysis framework, implementing a protein truncating variant (PTV) collapsing analysis
396 model⁴¹. We classified variants as PTVs if they had been annotated by SnpEff as:
397 exon_loss_variant, frameshift_variant, start_lost, stop_gained, stop_lost,
398 splice_acceptor_variant, splice_donor_variant, gene_fusion, bidirectional_gene_fusion,
399 rare_amino_acid_variant, and transcript_ablation.

400 We applied minor allele frequency filters to target rare variants; $MAF < 0.001$ in gnomAD
401 (overall and every population except OTH) and a leave-one-out $MAF < 0.001$ among our
402 combined case and control test cohort. For variants to qualify they had to also meet the
403 following QC filters: minimum site coverage 10X; annotation in CCDS transcripts (release
404 22); at least 80% alternate reads in homozygous genotypes; percent of alternate reads in
405 heterozygous variants ≥ 0.25 and ≤ 0.8 ; binomial test of alternate allele proportion departure
406 from 50% in heterozygous state $P > 1 \times 10^{-6}$; $GQ \geq 20$; $FS \leq 200$ (indels) ≤ 60 (SNVs);
407 $MQ \geq 40$; $QUAL \geq 30$; read position rank sum score ≥ -2 ; $MQRS \geq -8$; DRAGEN variant
408 status = PASS and $< 0.5\%$ test cohort carrier QC failure. If the variant was observed in
409 gnomAD exomes, we also applied the filters: variant site achieved tenfold coverage in $\geq 25\%$
410 of gnomAD exomes; achieved exome z-score ≥ -2.0 ; exome $MQ \geq 30$ and random forest
411 probability that the given variant is a true SNV or indel > 0.02 and > 0.01 respectively⁴⁵.

412 For the quantitative traits, and for each gene, the difference in mean between the carriers
413 and noncarriers of PTVs was determined by fitting a linear regression model, correcting for
414 age and sex. In addition to calculating individual statistics for MCPS and PGR, we also
415 meta-analysed the individual study effect sizes to generate a combined replication statistic
416 by using an inverse-variance fixed effect meta-analysis implemented in R using the `rma.uni()`
417 function from the package 'metafor' v3.8-1⁴⁶

418 **Phenome-wide analysis in UKBB**

419 We included binary and quantitative traits made available in the June 2022 UKB data
420 release, harmonizing the phenotype data as previously described⁴¹. This resulted in 11,690

421 phenotypes for analysis; as available on <https://azphewas.com>. Based on clinical relevance
422 we derived an additional three phenotypes.

423 For the purposes of UKB phenome-wide analyses of the four putatively novel genes, the
424 same data generation and QC processes described for MCPS and PGR were applied to
425 UKB exomes. Following Regeneron and AstraZeneca QC steps, 445,570 UKB exomes
426 remained. The phenome-wide analysis was performed in UKB participants of predominately
427 EUR descent, whom we identified based on a PEDDY-derived predicted probability of
428 European ancestry ≥ 0.95 who were within 4 SD of the means for the top four PCs. Based
429 on the predicted ancestry pruning, 419,391 UKB exomes were included in the phenome-
430 wide analyses of the four priority genes.

431 As described previously, we assessed the association between the 11,693 phenotypes with
432 genotypes at the four genes of interest, again using a PTV collapsing analysis model⁴¹,
433 classifying variants as PTVs using the same SnpEff definitions as described for the MCPS
434 and PGR analysis. For variants to qualify for inclusion in the model, we applied the same
435 MAF and QC filters used in MCPS and PGR, with the exception that due to the larger
436 sample size of UKB, only <0.01% of the test cohort carriers were permitted to fail QC.

437 **Association testing for other anthropometry phenotypes and protein expression level.**

438 We ran association tests between *APBA1* and *BSN* HC PTV carriers and BMI-associated
439 common variant (rs9843653) at the *BSN* locus carriers and a list of anthropometry
440 phenotypes in R v3.6.3 (**Table S5**) including the same covariates we used in our exome-
441 wide gene burden tests. We acquired the normalised protein expression data generated by
442 the Olink platform from the UKBB RAP^{23,24}. The detailed Olink proteomics assay, data
443 processing and quality control were described by Sun et al.²³ For the association tests
444 between *APBA1* and *BSN* PTV carriers and BMI-associated common variant (rs9843653) at
445 the *BSN* locus carriers and 1,463 protein expression levels, we added age², age*sex,
446 age²*sex, Olink batch, UK Biobank centre, UK Biobank genetic array, number of proteins
447 measured and the first 20 genetic principal components (PCs) as covariates as suggested
448 by Sun et al.²³ We chose the Bonferroni corrected p-value ($P < 3.42 \times 10^{-5}$ (0.05/1,463)) as the
449 threshold for the significant associations.

450 **BMI GWAS lookup and downstream analyses**

451 Identified genes were queried for proximal BMI GWAS signals, using data from the UK
452 Biobank, if within 500kb up- or downstream of the gene's start or end site. Any such signals
453 were further replicated in an independent BMI GWAS⁹.

454 We also performed colocalisation tests, using the Approximate Bayes Factor (ABF) method
455 in the R package “coloc” (version 5.1.0, 8) and blood gene expression level data from the
456 eQTLGen study¹⁶. Genomic regions were defined as $\pm 500\text{kb}$ around each gene and loci
457 exhibiting an H4 posterior probability >0.5 were considered to show evidence of
458 colocalisation.

459 Finally, we also used the GWAS data to calculate gene-level common variant associations,
460 using MAGMA⁴⁷. To do this, we used all common but non-synonymous (coding) variants
461 within a given gene. Gene-level scores were further collapsed into pathway-level
462 associations where appropriate.

463 **Interaction effect between PGS and PTV carrier status**

464 To examine whether there is an interaction effect between the PTV carrier status of *BSN* and
465 *APBA1*, we included an interaction term between PGS and the carrier status of *BSN* and
466 *APBA1* PTVs in a linear regression adjusted for sex, age and age squared and the first 10
467 PCs.

468 The polygenic score (PGS) was constructed for 419,581 individuals of white European
469 ancestry who had both genotype and exome sequencing data and a BMI record in the
470 UKBB. We used summary statistics of BMI from Locke et al.⁹, which included samples not in
471 the UKBB. Data was downloaded from the GIANT consortium. The summary statistics
472 included 2,113,400 SNPs with at least 50,000 samples in a cohort of 322,154 participants
473 of European ancestry. For the genotype data of UKBB participants, a light quality check
474 procedure was applied, where SNPs were removed if they had a MAF $<0.1\%$, HWE $<1e-6$ or
475 variants with more than 10% missingness genotypes. Additionally, SNPs that were
476 mismatched with those in the summary statistics (same rsID but different chromosome or
477 positions) were excluded. We used lassosum v4.0.5⁴⁸ to construct the PGS. The R squared
478 of the model including the PGS regressed on rank-based inverse normal transformed BMI
479 and adjusted for sex, age and age squared and the first 10 PCs as covariates was 11%.

480

481 **Cell lines and routine cell culture**

482

483 The KOLF2.1J human-induced pluripotent stem cell line and its derivatives⁴⁹ were
484 maintained on Geltrex (Thermo Fisher Scientific A1413202) coated plates in supplemented
485 StemFlex media (Thermo Fisher Scientific A3349401) with daily medium changes. For
486 passaging, the cells were washed with PBS and treated with TrypLE Express (Gibco,
487 12604021) at 37°C for 3 min. The cells were re-suspended in StemFlex media supplemented

488 with 10 μ M ROCK Inhibitor Y-27632 dihydrochloride (Stemcell Technologies, 72304). ROCK
489 inhibitor was removed the following day with growth medium without the Y-27632. Unless
490 otherwise stated, cells were split at a 1:5 ratio. The absence of mycoplasma was confirmed
491 using an EZ-PCR Mycoplasma Test Kit (Biological Industries, 20-700-20) following the
492 manufacturer's instructions.

493

494 **CRISPR-Cas9-mediated targeting of BSN**

495

496 Two different small guide RNAs (sgRNA) with high predicted on-target and low predicted off-
497 target activity were designed using CRISPick
498 (<https://portals.broadinstitute.org/gppx/crispick/public>). For the production of sgRNAs, a 120
499 nucleotide oligo (Integrated DNA Technologies Inc.) including the SP6 promoter, sgRNA
500 sequences, and scaffold region were used as a template for synthesis by *in vitro*
501 transcription using the MEGAscript SP6 kit (Thermo Fisher, AM1330) as previously
502 described⁵⁰. The resulting sgRNAs were purified using the E.Z.N.A miRNA purification kit
503 (Omega Bio-tek, R7034-01), eluted in RNase-free water, and stored at -80°C. Since sgRNAs
504 vary in their efficacy, the relative cutting efficiencies of the two sgRNAs were tested in *in vitro*
505 cleavage assays as previously described⁵⁰. We selected the sgRNAs that showed activity at
506 the lowest Cas9 concentration for transfection into hPSC cells. Single-stranded
507 oligodeoxynucleotides (ssODN) templates (100bp) were constructed by IDT containing
508 target mutations in the middle and silent mutations within PAM sites. All sequences of the
509 primers, sgRNA, ssODN donors used in the study are listed in **(Table S15)**.

510

511 **CRISPR-Cas9 ribonucleoprotein (RNP) complex-mediated editing in hESCs**

512

513 To genetically edit the KOLF2.1J cells by homology-directed repair (HDR)^{51,52}, 3 μ g purified
514 sgRNA was mixed with 4 μ g of recombinant Cas9 nuclease (IDT 1081060) for 45 min at
515 room temperature to form stable ribonucleoprotein (RNP) complexes. The complex together
516 with 1 μ l of 100 μ M ssODN was then transferred to a 20 μ l single-cell suspension of 2×10^5
517 hESCs in P3 nucleofection solution and electroporated using Amaxa 4D-Nucleofector™
518 (Lonza) with program CA137. Transfected cells were seeded onto Geltrex-coated 24 well
519 plates containing a pre-warmed StemFlex medium containing Revitacell (100x, Gibco
520 A2644501) and Penicillin/Streptavidin (ThermoFisher Scientific, 15140-122). HDR enhancer
521 (IDT 1081072) was added to the cells at a 30 μ M final concentration for each well. The
522 following day medium was changed to growth medium without Pen/Strep and Revitacell. To
523 increase HDR efficiency, cells were cultured under cold shock conditions (32°C at 5% CO₂ in
524 air atmosphere) for 48hr post transfection. Cells were given approximately 5-6 days to

525 recover before single cells were then distributed into multiple Geltrex (1:40)-coated 96 well
526 plates by an Aria-Fusion sorter with a 100 µm nozzle. After ~2 weeks, viable clonally-derived
527 colonies were consolidated into duplicate 96 well plates to allow parallel cell
528 cryopreservation and genomic DNA extraction as previously described^{50,52}.

529

530 **Generation and sequencing of pooled amplicons**

531

532 Genomic DNA (gDNA) was extracted using HotShot buffer as previously described⁵⁰. The
533 target regions were amplified from gDNA using locus-specific primers to generate amplicons
534 approximately 150-200 bp in length. These “first-round” primers contained universal Fluidigm
535 linker sequences at their 5'-end with the following sequences: Forward primer: 5'-
536 aactgacgacatggttctaca -3', Reverse primer: 5'- tacgtagcagagacttggtct-3'. Specifically, 20 µl
537 PCR reactions were set up in 96 well plates using 0.5U Phusion Hot Start II High-Fidelity
538 DNA Polymerase (ThermoFisher Scientific, F-549L), 2 µl of extracted gDNA as template, 2
539 µl 5x GC buffer, 0.2 mM dNTPs, 2µM primers, and 3% DMSO, and run on the following
540 programme: 98°C 30sec, followed by 24 cycles of (95°C 10 sec, 72°C 20 sec/ decreased by
541 0.5°C per cycle, 72°C 15 sec) than 12 cycles of (98°C 10sec, 60°C 30 sec, 72°C 15 sec)
542 and 72°C 5 min. In the second round of PCR (indexing PCR), Fluidigm barcoding primers
543 were attached to the amplicons to uniquely identify each clone. 2 µl linker PCR product
544 diluted 1:10 was transferred to another 96-well PCR plate to perform this indexing PCR in 10
545 µl reactions containing 0.8 µM of Fluidigm barcoding primers, 2 µl 10x GC buffer, 0.2 mM
546 dNTPs 3% DMSO and 0.5U Phusion Hot Start II polymerase. The PCR programme was
547 95°C 2 min, 16 cycles of (95°C 20 sec, 60°C 20 sec, 72°C 25 sec), 72°C 3 min. For
548 sequencing library preparation, barcoded PCR products were combined in equal proportion
549 based on estimation of band intensity on a 2% agarose gel, and the combined pool of PCR
550 products was purified in a single tube using Ampure XP beads (Invitrogen 123.21D) at 1:1
551 (V/V) to the pooled sample and eluted in 25 µl of water according to the manufacturer's
552 instructions. Library purity was confirmed by nanodrop, and final library concentration was
553 measured using the Agilent Bioanalyzer (High Sensitivity Kit, Agilent 5067-4626) and diluted
554 to 20 nM. Pooled libraries could be combined with other library pools adjusted to 20 nM, and
555 the resulting “superpool” volume was adjusted to a final volume of 20 µl before sequencing
556 which is performed by the Genomics Core, Cancer Research UK Cambridge Institute.
557 GenEditID platform⁵² was used for identification of the BSN P399X heterozygous and wild
558 type (WT) clones.

559

560

561

562 **Hypothalamic neuron differentiation protocol**

563

564 Gene edited *BSN* P399X heterozygous and WT clones were differentiated into
565 hypothalamic-like neurons as previously described^{53,54}. Briefly, cells were cultured overnight
566 on 10cm plate Geltrex coated plates (9.5×10^5 cells/well for 6-well plates) in Stemflex™ with
567 10 μ M ROCK inhibitor. Next day, neuroectoderm differentiation was initiated by dual SMAD
568 inhibition using XAV939 (Stemgent 04-1946), LDN 193289 (Stemgent 04-0074) and SB
569 431542 (Sigma Aldrich S4317) and Wnt signaling inhibition using XAV939 (Stemgent 04-
570 1946) in an in-house neural differentiation N2B27 medium⁵⁴. From day 2 to day 7, cells were
571 directed 'towards ventral diencephalon' with Sonic hedgehog activation, by the addition of
572 Smoothened agonist SAG (1 μ M Thermo Fisher Scientific 56-666) and purmorphamine
573 (PMC, 1 μ M Thermo Fisher Scientific 54-022), with SMAD and Wnt inhibition molecules
574 gradually replaced with N2 B27 medium changed every 2 days. At Day 8, the cells were
575 switched into N2B27 with 5 μ M DAPT (Sigma Aldrich D5942) to exit cell cycle. On Day 14,
576 the cells were harvested with TrypLE™ supplemented with papain (Worthington LK003176)
577 and re-plated onto laminin-coated 6-well plates at a density of 3×10^6 cells per well in the
578 presence of maturation medium containing brain-derived neurotrophic factor BDNF
579 (10ng/ml, Sigma) containing N2B27. On day 16 media was changed to Synptojuice 1
580 (N2B27, 10ng/ml BDNF, 2 μ M PD0332991 (Sigma Aldrich, PZ0199), 5 μ M DAPT, 370 μ M
581 CaCl_2 (Sigma Aldrich, 21115), 1 μ M LM22A4 (Tocris, 4607), 2 μ M CHIR99021 (Cell
582 Guidance Systems, SM13), 300 μ M GABA (Tocris, 0344), 10 μ M NKH447 (Sigma Aldrich,
583 N3290)). Cells were maintained in Synptojuice 1 for a week before being changed to
584 Synptojuice 2 (N2B27, 10ng/ml BDNF, 2 μ M, 370 μ M CaCl_2 1 μ M LM22A4, 2 μ M
585 CHIR99021). Cells were then maintained in Synptojuice 2 until day 36, with media renewal
586 every second day throughout the differentiation and maturation period.

587

588 **Single nucleus RNA-sequencing**

589

590 On day 36, cells were dissociated using TrypLE™ and papain mixture, pelleted, and nuclei
591 were isolated following a 10x Genomics standardised protocol for single nucleus RNA
592 Sequencing (NucSeq) as previously reported⁵⁵. Sequencing libraries for the 6 (3 x wild type
593 and 3 x *BSN* P399X Het) single-nuclei suspension samples were generated using 10X
594 Genomics Chromium Single-Cell 3' Reagent kits (Pleasanton, CA, USA, version 3)
595 according to the standardised protocol. Briefly, nuclear suspensions were loaded onto the
596 chromium chip along with gel beads, partitioning oil, and master mix to generate GEMs
597 containing free RNA. RNA from lysed nuclei was reverse transcribed and cDNA was PCR
598 amplified for 19 cycles. The amplified cDNA was used to generate a barcoded 3' library

599 according to the manufacturer's protocol, and paired-end sequencing was performed using
600 an Illumina NovaSeq 6000 (San Diego, CA, USA, read 1: 28 bp and read 2: 91 bp). Library
601 preparation and sequencing was performed by the Genomics Core, Cancer Research UK
602 Cambridge Institute.

603

604 **Single-cell clustering and differential gene expression analysis.**

605

606 For the 10X generated NucSeq datasets, Cellranger Version 6.0.1 was used to map
607 sequence reads to the human genome GRCh38 and perform the UMI and gene-level counts
608 against Ensembl gene model V100. The raw count matrices generated by the software were
609 then used for downstream analyses. A downstream analysis on the raw count matrices was
610 performed using the Seurat package version 4.0.3.⁵⁶ Nuclei expressing less than 500
611 features, or less than 800 transcripts were removed as low-quality reads. Nuclei with more
612 than 10000 different features were removed as these were likely doublets. Any nuclei
613 expressing more than 5% mitochondrial RNA were excluded from the analysis. The
614 SCTransform package was used for normalization and variance stabilization of the data,
615 using regularized negative binomial regression⁵⁷. The data was integrated prior to PCA,
616 followed by unsupervised clustering analysis using the Louvain algorithm and Uniform
617 Manifold Approximation and Projection (UMAP) dimension reduction. Marker genes for each
618 cluster were identified using Wilcoxon's rank-sum test and receiver-operating curve (ROC)
619 analyses. Adjustment of p-values was performed using Bonferroni correction based on the
620 total number of genes in the dataset. Clusters with a high expression of a conventional
621 neuronal marker *RBF3* were separated into a new object and PCA, followed by
622 unsupervised clustering analysis using the Louvain algorithm and Uniform Manifold
623 Approximation and Projection (UMAP) dimension reduction was repeated. After that
624 differential expression of genes between nuclei from the wild type and *BSN P399X* Het
625 nuclei within each cluster was analysed using Negative Binomial GLM fitting and Wald
626 statistics with the help of the DESeq2 package⁵⁸. The p-values attained by the Wald test
627 were corrected for multiple testing using the Benjamini and Hochberg method to generate
628 adjusted p-values. Genes with a Log2FC of <-1 or >1 and with a p-value adjusted < 0.05
629 were selected for performing pathway analysis. The Metascape⁵⁹ pathway analysis was
630 used to identify pathways that were either upregulated or downregulated between the wild
631 type and *BSN P399X* Het nuclei.

632

633

634

635 **References**

- 636 1. Blüher, M. Obesity: global epidemiology and pathogenesis. *Nature Reviews*
637 *Endocrinology* 2019 15:5 15, 288–298 (2019).
- 638 2. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. *New*
639 *England Journal of Medicine* 377, 13–27 (2017).
- 640 3. Di Cesare, M. *et al.* The epidemiological burden of obesity in childhood: A worldwide
641 epidemic requiring urgent action. *BMC Med* 17, 1–20 (2019).
- 642 4. Zhang, Y. *et al.* Positional cloning of the mouse obese gene and its human
643 homologue. *Nature* 372, 425–432 (1994).
- 644 5. Loos, R. J. F. & Yeo, G. S. H. The genetics of obesity: from discovery to biology. *Nat*
645 *Rev Genet* 23, 120–133 (2022).
- 646 6. Vaisse, C., Clement, K., Guy-Grand, B. & Froguel, P. A frameshift mutation in human
647 MC4R is associated with a dominant form of obesity. *Nature Genetics* 1998 20:2 20,
648 113–114 (1998).
- 649 7. Yeo, G. S. H. *et al.* A frameshift mutation in MC4R associated with dominantly
650 inherited human obesity. *Nature Genetics* 1998 20:2 20, 111–112 (1998).
- 651 8. Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and
652 body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* 27,
653 3641–3649 (2018).
- 654 9. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity
655 biology. *Nature* 2015 518:7538 518, 197–206 (2015).
- 656 10. Akbari, P. *et al.* Sequencing of 640,000 exomes identifies GPR75 variants associated
657 with protection from obesity. *Science* (1979) 373, (2021).
- 658 11. Povysil, G. *et al.* Rare-variant collapsing analyses for complex traits: guidelines and
659 applications. *Nature Reviews Genetics* 2019 20:12 20, 747–759 (2019).
- 660 12. Stankovic, S. *et al.* Genetic susceptibility to earlier ovarian ageing increases de novo
661 mutation rate in offspring. *medRxiv* 2022.06.23.22276698 (2022)
662 doi:10.1101/2022.06.23.22276698.
- 663 13. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
664 *Nature* 2018 562:7726 562, 203–209 (2018).
- 665 14. Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity
666 of Rare Missense Variants. *Am J Hum Genet* 99, 877–885 (2016).
- 667 15. Loh, P. R. *et al.* Efficient Bayesian mixed-model analysis increases association power
668 in large cohorts. *Nature Genetics* 2015 47:3 47, 284–290 (2015).
- 669 16. Võsa, U. *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic
670 loci and polygenic scores that regulate blood gene expression. *Nature Genetics* 2021
671 53:9 53, 1300–1310 (2021).
- 672 17. Tapia-Conyer, R. *et al.* Cohort Profile: The Mexico City Prospective Study. *Int J*
673 *Epidemiol* 35, 243–249 (2006).

- 674 18. Ziyatdinov, A. *et al.* Genotyping, sequencing and analysis of 140,000 adults from the
675 Mexico City Prospective Study. *bioRxiv* 2022.06.26.495014 (2022)
676 doi:10.1101/2022.06.26.495014.
- 677 19. Gardner, E. J. *et al.* Damaging missense variants in IGF1R implicate a role for IGF-1
678 resistance in the etiology of type 2 diabetes. *Cell Genomics* **2**, 100208 (2022).
- 679 20. Zhao, Y. *et al.* GIGYF1 loss of function is associated with clonal mosaicism and
680 adverse metabolic health. *Nature Communications* 2021 12:1 **12**, 1–6 (2021).
- 681 21. Bedogni, G. *et al.* The fatty liver index: A simple and accurate predictor of hepatic
682 steatosis in the general population. *BMC Gastroenterol* **6**, 1–7 (2006).
- 683 22. Lee, J. H. *et al.* Hepatic steatosis index: A simple screening tool reflecting
684 nonalcoholic fatty liver disease. *Digestive and Liver Disease* **42**, 503–508 (2010).
- 685 23. Sun, B. B. *et al.* Genetic regulation of the human plasma proteome in 54,306 UK
686 Biobank participants. *bioRxiv* 2022.06.17.496443 (2022)
687 doi:10.1101/2022.06.17.496443.
- 688 24. Dhindsa, R. S. *et al.* Influences of rare protein-coding genetic variants on the human
689 plasma proteome in 50,829 UK Biobank participants. *bioRxiv* 2022.10.09.511476
690 (2022) doi:10.1101/2022.10.09.511476.
- 691 25. van der Klaauw, A. A. *et al.* Human Semaphorin 3 Variants Link Melanocortin Circuit
692 Development and Energy Balance. *Cell* **176**, 729-742.e18 (2019).
- 693 26. Orthofer, M. *et al.* Identification of ALK in Thinness. *Cell* **181**, 1246-1262.e22 (2020).
- 694 27. Richardson, T. G., Sanderson, E., Elsworth, B., Tilling, K. & Smith, G. D. Use of
695 genetic variation to separate the effects of early and later life adiposity on disease
696 risk: mendelian randomisation study. *BMJ* **369**, (2020).
- 697 28. Butz, S., Okamoto, M. & Südhof, T. C. A tripartite protein complex with the potential to
698 couple synaptic vesicle exocytosis to cell adhesion in brain. *Cell* **94**, 773–782 (1998).
- 699 29. Tom Dieck, S. *et al.* Bassoon, a Novel Zinc-finger CAG/Glutamine-repeat Protein
700 Selectively Localized at the Active Zone of Presynaptic Nerve Terminals. *Journal of*
701 *Cell Biology* **142**, 499–509 (1998).
- 702 30. Altmock, W. D. *et al.* Functional inactivation of a fraction of excitatory synapses in mice
703 deficient for the active zone protein bassoon. *Neuron* **37**, 787–800 (2003).
- 704 31. Hashida, H. *et al.* Cloning and Mapping of ZNF231, a Novel Brain-Specific Gene
705 Encoding Neuronal Double Zinc Finger Protein Whose Expression Is Enhanced in a
706 Neurodegenerative Disorder, Multiple System Atrophy (MSA). *Genomics* **54**, 50–58
707 (1998).
- 708 32. Yabe, I. *et al.* Mutations in bassoon in individuals with familial and sporadic
709 progressive supranuclear palsy-like syndrome. *Scientific Reports* 2018 8:1 **8**, 1–13
710 (2018).
- 711 33. De Lauzon-Guillain, B. *et al.* Mediation and modification of genetic susceptibility to
712 obesity by eating behaviors. *Am J Clin Nutr* **106**, 996–1004 (2017).
- 713 34. Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank
714 participants. *Nature* 2021 599:7886 **599**, 628–634 (2021).

- 715 35. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, 1–4
716 (2021).
- 717 36. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**, 1–14
718 (2016).
- 719 37. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting
720 the deleteriousness of variants throughout the human genome. *Nucleic Acids Res* **47**,
721 D886–D894 (2019).
- 722 38. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
723 141,456 humans. *Nature* **2020 581:7809 581**, 434–443 (2020).
- 724 39. Morales, J. *et al.* A joint NCBI and EMBL-EBI transcript set for clinical genomics and
725 research. *Nature* **2022 604:7905 604**, 310–315 (2022).
- 726 40. Cingolani, P. *et al.* A program for annotating and predicting the effects of single
727 nucleotide polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster*
728 strain w1118; iso-2; iso-3. *Fly (Austin)* **6**, 80–92 (2012).
- 729 41. Wang, Q. *et al.* Rare variant contribution to human disease in 281,104 UK Biobank
730 exomes. *Nature* **2021 597:7877 597**, 527–532 (2021).
- 731 42. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association
732 studies. *Bioinformatics* **26**, 2867–2873 (2010).
- 733 43. Pedersen, B. S. & Quinlan, A. R. Who's Who? Detecting and Resolving Sample
734 Anomalies in Human DNA Sequencing Studies with Peddy. *Am J Hum Genet* **100**,
735 406–413 (2017).
- 736 44. Auton, A. *et al.* A global reference for human genetic variation. *Nature* **2015 526:7571**
737 **526**, 68–74 (2015).
- 738 45. Chen, S. *et al.* A genome-wide mutational constraint map quantified from variation in
739 76,156 human genomes. *bioRxiv* 2022.03.20.485034 (2022)
740 doi:10.1101/2022.03.20.485034.
- 741 46. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *J Stat*
742 *Softw* **36**, 1–48 (2010).
- 743 47. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized
744 Gene-Set Analysis of GWAS Data. *PLoS Comput Biol* **11**, e1004219 (2015).
- 745 48. Mak, T. S. H., Porsch, R. M., Choi, S. W., Zhou, X. & Sham, P. C. Polygenic scores
746 via penalized regression on summary statistics. *Genet Epidemiol* **41**, 469–480 (2017).
- 747 49. Pantazis, C. B. *et al.* A reference human induced pluripotent stem cell line for large-
748 scale collaborative studies. *Cell Stem Cell* **29**, 1685-1702.e22 (2022).
- 749 50. Santos, D. P., Kiskinis, E., Eggan, K. & Merkle, F. T. Comprehensive Protocols for
750 CRISPR/Cas9-based Gene Editing in Human Pluripotent Stem Cells. *Curr Protoc*
751 *Stem Cell Biol* **38**, 5B.6.1-5B.6.60 (2016).
- 752 51. Skarnes, W. C., Pellegrino, E. & McDonough, J. A. Improving homology-directed
753 repair efficiency in human stem cells. *Methods* **164–165**, 18–28 (2019).

- 754 52. Xue, Y. *et al.* GenEditID: an open-access platform for the high-throughput
755 identification of CRISPR edited cell clones. *bioRxiv* 657650 (2019)
756 doi:10.1101/657650.
- 757 53. Merkle, F. T. *et al.* Generation of neuropeptidergic hypothalamic neurons from human
758 pluripotent stem cells. *Development* **142**, 633–643 (2015).
- 759 54. Kirwan, P., Jura, M. & Merkle, F. T. Generation and Characterization of Functional
760 Human Hypothalamic Neurons. *Curr Protoc Neurosci* **81**, 3.33.1-3.33.24 (2017).
- 761 55. Dowsett, G. K. C. *et al.* A survey of the mouse hindbrain in the fed and fasted states
762 using single-nucleus RNA sequencing. *Mol Metab* **53**, 101240 (2021).
- 763 56. Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
764 transcriptomic data across different conditions, technologies, and species. *Nature*
765 *Biotechnology* 2018 36:5 **36**, 411–420 (2018).
- 766 57. Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell
767 RNA-seq data using regularized negative binomial regression. *Genome Biol* **20**, 1–15
768 (2019).
- 769 58. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
770 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 1–21 (2014).
- 771 59. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the analysis of
772 systems-level datasets. *Nature Communications* 2019 10:1 **10**, 1–10 (2019).
- 773